Ossiam Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ossiam increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,548 shares of the medical equipment provider’s stock after purchasing an additional 396 shares during the quarter. Ossiam’s holdings in Zimmer Biomet were worth $692,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB grew its stake in Zimmer Biomet by 7.7% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 6,196 shares of the medical equipment provider’s stock valued at $669,000 after purchasing an additional 442 shares during the period. B. Riley Wealth Advisors Inc. raised its position in Zimmer Biomet by 17.5% in the third quarter. B. Riley Wealth Advisors Inc. now owns 2,404 shares of the medical equipment provider’s stock worth $260,000 after acquiring an additional 358 shares during the period. GAMMA Investing LLC grew its position in shares of Zimmer Biomet by 67.6% during the 4th quarter. GAMMA Investing LLC now owns 2,298 shares of the medical equipment provider’s stock valued at $243,000 after acquiring an additional 927 shares during the period. Central Pacific Bank Trust Division raised its holdings in shares of Zimmer Biomet by 7.4% in the 4th quarter. Central Pacific Bank Trust Division now owns 14,525 shares of the medical equipment provider’s stock worth $1,534,000 after purchasing an additional 1,000 shares during the period. Finally, Nordea Investment Management AB grew its holdings in Zimmer Biomet by 3.9% during the fourth quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock valued at $1,732,000 after purchasing an additional 609 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.95% of the stock is owned by company insiders.

Analysts Set New Price Targets

ZBH has been the subject of several research reports. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Stifel Nicolaus upped their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Royal Bank of Canada lowered their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Raymond James decreased their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, Truist Financial reiterated a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Stock Down 1.6 %

Shares of NYSE:ZBH opened at $96.38 on Tuesday. Zimmer Biomet Holdings, Inc. has a 12-month low of $93.10 and a 12-month high of $123.96. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock’s 50-day moving average price is $105.87 and its 200-day moving average price is $106.68. The stock has a market capitalization of $19.07 billion, a P/E ratio of 21.66, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company posted $2.20 EPS. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.00%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.